Anticipating a Renaissance in Neuroscience Drug Development


Henry J. Riordan, PhD | Natalia Drosopoulou, PhD | Christine Moore, PhD

Neuroscience clinical development is experiencing a surge in funding after nearly a decade of dropping rates. Big pharma companies like Acadia, Biogen, and Novartis are turning their investments towards these programs, and we’ve seen some recent notable successes in treatments for neurological diseases.

Read our article with the Journal for Clinical Studies to learn more about the success we are seeing and hear why we expect this uptick in funding will continue. 

Your form has been successfully submitted! Click the button below to access.
READ MORE
Henry J. Riordan, PhD
MEET THE AUTHOR

Henry J. Riordan, PhD

Chief Development Officer
LEARN MORE
Natalia Drosopoulou, PhD
MEET THE AUTHOR

Natalia Drosopoulou, PhD

Vice President, Project Management, Neuroscience
LEARN MORE
Christine Moore, PhD
MEET THE AUTHOR

Christine Moore, PhD

Vice President, Neuroscience, Scientific Solutions
LEARN MORE